Adverse reactions to intravenous iodinated contrast media: a prospective study
Keywords:
Adverse Reactions, Intravenous Iodinated Contrast Media, Sodium Meglumine DiatrizoateAbstract
Background: Adverse reactions to intravenous iodinated contrast media may be classified as general and organ-specific, such as contrast-induced nephrotoxicity. General adverse reactions may be sub classified into acute and delayed types. Acute general adverse reactions can range from transient minor reactions to life-threatening severe reactions. This study was done to determine clinical adverse effects of the iodinated contrast media.
Methods: Data of 899 consecutive patients at C.U. Shah Medical College and Hospital, Surendranagar, who received sodium meglumine diatrizoate intravenous iodinated contrast media during the period of May 2011 to April 2012, were collected for any adverse drug reactions.
Results: Out of 899, 189 patients developed adverse contrast reactions. The incidences of mild, moderate and severe adverse reactions were 19.47%, 1.33% and 0.28%, respectively. There were no differences in the incidence of adverse reactions according to gender (males 21.1%; females 20.7%; p= >0.05) or age (p= >0.05). The incidence of adverse reactions was significantly higher in patients with a history of previous reactions (50%) than in those with no history (21.25%; p= <0.05).
Conclusions: The skin was the most commonly affected site of reactions. In reactions, mild forms were more common compared to moderate and severe.
References
Diatrizoic acid - Compound Summary. Available at http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2140. Accessed 19 June 2012.
Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol 1991;157:1153-61.
Webb JAW, Stacul F, Thomsen HS, Morcos SK. Late adverse reactions to intravascular iodinated contrast media. Eur Radiol 2003;13:181-4.
American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, 5th ed, American College of Radiology, Reston, VA 2004:5.
Shehadi WH, Toniolo G. Adverse reactions to contrast media: a report from the Committee on Safety of Contrast Media of the International Society of Radiology. Radiology 1980;137:299-302.
Ansell G, Tweedie MC, West CR, Evans P, Couch L. The current status of reactions to intravenous contrast media. Invest Radiol 1980;15(6 Suppl):S32-9.
Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution and elimination. In: Hardman JG, Limbird LE, et al, editors. The pharmacological basis of therapeutics. New York: McGraw Hill, 1996:3-27.
Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997;49:369-79.
Jacobsson BF, Jorulf H, Kalantar MS, Narasimham DL. Nonionic versus ionic contrast media in intravenous urography: clinical trial in 1000 consecutive patients. Radiology 1988;167:601-5.
Higashi S, Takizawa K, Suzuki S, Nagashima J, Tamura S, Ishikawa M, et al. Prospective study of adverse reactions to contrast media administered intravenously: a comparison of low-osmolality and high-osmolality contrast media. Nippon Igaku Hoshasen Gakkai Zasshi 1988;48:1364-70.
Oi H, Yamazaki H, Matsushita M. Delayed vs. immediate adverse reactions to ionic and non-ionic low osmolality contrast media. Radiat Med 1997;15:23-7.
Shehadi WH. Adverse reactions to intravascularly administered contrast media. A comprehensive study based on a prospective survey. Am J Roentgenol Radium Ther Nucl Med. 1975;124:145-52.
Palmer FJ. The RACR survey of intravenous contrast media reactions: Final report. Australas Radiol 1988;32:426-8.
Spring DB, Bettmann MA, Barkan HE. Nonfatal adverse reactions to iodinated contrast media: spontaneous reporting to the U.S. Food and Drug Administration, 1978-1994. Radiology 1997;204:325-32.
Cohan RH, Leder RA, Ellis JH. Treatment of adverse reactions to radiographic contrast media in adults. Radiol Clin North Am 1996;34:1055-76.
